| MEDICARE-PART-D-COMPANY |
MEDICARE-PART-D-COMPANY |
85%
|
be attributed to a decrease in utilization of the product through insurance formularies, specifically Medicare Part D. Company’s retail pharmacy operating segment, Marley Drug, Gateway Pharmacy and W… |
| MRK |
Merck & Co., Inc. |
72%
|
ces performed by the Company’s customers, including the amount of such payment; · the Federal False Claims Act, which imposes civil and criminal liability on individuals and entities who submit, or c… |
| MRK |
Merck & Co., Inc. |
72%
|
Reciprocal relationship from MRK graph: Reciprocal relationship from MCUJF graph: Reciprocal relationship from MRK graph: Reciprocal relationship from MCUJF graph: Reciprocal relationship from MRK gr… |
| APOTEX-INC-VIVENTIA-BIOTECH-INC-GENESYS-PHARMA-I |
APOTEX-INC-VIVENTIA-BIOTECH-INC-GENESYS-PHARMA-I |
62%
|
ct to differing interpretations of applicable tax laws and regulations and tax treaties, as they relate to the amount, timing or inclusion of revenues and expenses, or the sustainability of income ta… |
| CADILA-HEALTHCARE-LTD |
CADILA-HEALTHCARE-LTD |
62%
|
is used for the treatment of acute coronary syndrome including unstable angina, which is characterized by chest pain when one is at rest, and non‑Q‑wave myocardial infarction. In September 2019, the … |
| CHIESI-FARMACEUTICS-S-P-A-INC |
CHIESI-FARMACEUTICS-S-P-A-INC |
62%
|
ces performed by the Company’s customers, including the amount of such payment; · the Federal False Claims Act, which imposes civil and criminal liability on individuals and entities who submit, or c… |
| C-ORGANIZATIONAL-STRUCTURE-MEDICURE-INTERNATIONA |
C-ORGANIZATIONAL-STRUCTURE-MEDICURE-INTERNATIONA |
62%
|
ug) to the Company during the year ended December 31, 2024. Maintaining AGGRASTAT ® sales in the United States The Company continues to work to maintain the sales of AGGRASTAT ® in the United States.… |
| GATEWAY-MEDICAL-PHARMACY-INC |
GATEWAY-MEDICAL-PHARMACY-INC |
62%
|
is used for the treatment of acute coronary syndrome including unstable angina, which is characterized by chest pain when one is at rest, and non‑Q‑wave myocardial infarction. In September 2019, the … |
| GATEWAY-PHARMACY-INC |
GATEWAY-PHARMACY-INC |
62%
|
escription of the matter On March 11, 2025 and June 16, 2025, the Company completed its acquisitions of Gateway Pharmacy Inc. (“Gateway”) and West Olympia Pharmacy, LLC (“West Olympia”) respectively … |
| HOUSE-WHITE-PARK-ROAD-BRIDGETOWN-BARBADOS-MEDICU |
HOUSE-WHITE-PARK-ROAD-BRIDGETOWN-BARBADOS-MEDICU |
62%
|
ug) to the Company during the year ended December 31, 2024. Maintaining AGGRASTAT ® sales in the United States The Company continues to work to maintain the sales of AGGRASTAT ® in the United States.… |
| LIMEGROVE-CENTRE-HOLETOWN-ST-JAMES-BARBADOS-MEDI |
LIMEGROVE-CENTRE-HOLETOWN-ST-JAMES-BARBADOS-MEDI |
62%
|
ug) to the Company during the year ended December 31, 2024. Maintaining AGGRASTAT ® sales in the United States The Company continues to work to maintain the sales of AGGRASTAT ® in the United States.… |
| MARLEY-DRUG-INC |
MARLEY-DRUG-INC |
62%
|
is used for the treatment of acute coronary syndrome including unstable angina, which is characterized by chest pain when one is at rest, and non‑Q‑wave myocardial infarction. In September 2019, the … |
| MEDICURE-INTERNATIONAL-INC |
MEDICURE-INTERNATIONAL-INC |
62%
|
ug) to the Company during the year ended December 31, 2024. Maintaining AGGRASTAT ® sales in the United States The Company continues to work to maintain the sales of AGGRASTAT ® in the United States.… |
| MEDICURE-INTERNATIONAL-INC-MEDICURE-PHARMA-INC |
MEDICURE-INTERNATIONAL-INC-MEDICURE-PHARMA-INC |
62%
|
is used for the treatment of acute coronary syndrome including unstable angina, which is characterized by chest pain when one is at rest, and non‑Q‑wave myocardial infarction. In September 2019, the … |
| MEDICURE-PHARMA-INC |
MEDICURE-PHARMA-INC |
62%
|
is used for the treatment of acute coronary syndrome including unstable angina, which is characterized by chest pain when one is at rest, and non‑Q‑wave myocardial infarction. In September 2019, the … |
| WAVERLEY-PHARMA-INC-DIAMEDICA-INC-MIRACULINS-INC |
WAVERLEY-PHARMA-INC-DIAMEDICA-INC-MIRACULINS-INC |
62%
|
ct to differing interpretations of applicable tax laws and regulations and tax treaties, as they relate to the amount, timing or inclusion of revenues and expenses, or the sustainability of income ta… |
| WEST-OLYMPIA-PHARMACY-LLC |
WEST-OLYMPIA-PHARMACY-LLC |
62%
|
is used for the treatment of acute coronary syndrome including unstable angina, which is characterized by chest pain when one is at rest, and non‑Q‑wave myocardial infarction. In September 2019, the … |
